专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20180044399A1 INHIBITORY CHIMERIC ANTIGEN RECEPTORS 审中-公开
公开(公告)号：US20180044399A1
公开(公告)日：2018-02-15
申请号：US15525906
申请日：2015-11-09
申请人： RINAT NEUROSCIENCE CORP. , CELLECTIS
发明人： Arvind RAJPAL , Shobha Chowdary POTLURI , Laurent POIROT , Alexandre JUILLERAT , Thomas Charles PERTEL , Donna Marie STONE , Barbra Johnson SASU
IPC分类号： C07K14/705 , C07K14/725 , A61K35/17 , C07K16/28 , C12N5/0783
CPC分类号： C07K14/70503 , A61K35/17 , A61K2039/5156 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/2803 , C07K16/3069 , C07K2317/622 , C07K2317/76 , C07K2319/03 , C07K2319/70 , C07K2319/74 , C12N5/0636 , C12N2510/00
摘要： The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or

2. 发明申请

US20130071921A1 ANTIBODIES SPECIFIC FOR DKK-1 AND THEIR USES 失效
标题翻译： DKK-1特异性抗体及其用途
公开(公告)号：US20130071921A1
公开(公告)日：2013-03-21
申请号：US13680569
申请日：2012-11-19
申请人： PFIZER INC. , RINAT NEUROSCIENCE CORP.
发明人： Vishwas Madhav PARALKAR , Donna Marie STONE , Mei LI , Jaume PONS
IPC分类号： C07K16/28 , C12N15/85 , C12N15/70
CPC分类号： C07K16/28 , A61K2039/505 , C07K16/18 , C07K2317/24 , C07K2317/33 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N15/70 , C12N15/85
摘要： The present invention provides antibodies and fragments thereof that bind to Dkk-1 and, in particular, to humanized antibodies and fragments thereof that bind to Dkk-1 and, even more particularly to fully humanized antibodies and immunologically functional fragments that bind to Dkk-1. Also provided are antibodies and fragments thereof which compete with the binding of an anti-mouse Dkk-1 monoclonal antibody for binding to Dkk-1+ cells. Also provided are nucleic acids encoding anti-Dkk-1 antibodies or fragments thereof, as well as expression vectors and host cells incorporating these nucleic acids for the recombinant expression of anti-Dkk-1 antibodies and fragments thereof. Also provided are methods of preparing the antibodies and fragments thereof of the invention. Also provided are bone anabolic agents. Pharmaceutical compositions comprising the antibodies or fragments thereof of the invention are also provided. Further provided are methods of treating diseases, conditions and disorders, such as bone disorders, which result in a loss of bone. Methods of treating or preventing a loss of bone mass, methods of inducing increased bone mass, and methods of inducing Wnt activity are also provided.
摘要翻译：本发明提供了与Dkk-1结合的抗体及其片段，特别是结合Dkk-1的人源化抗体及其片段，更具体地，涉及与Dkk-1结合的完全人源化抗体和免疫功能片段。还提供了与抗小鼠Dkk-1单克隆抗体与Dkk-1 +细胞的结合竞争的抗体及其片段。还提供了编码抗-Dkk-1抗体或其片段的核酸，以及掺入这些核酸用于重组表达抗-Dkk-1抗体及其片段的表达载体和宿主细胞。还提供了制备本发明的抗体及其片段的方法。还提供骨合成代谢剂。还提供了包含本发明的抗体或其片段的药物组合物。还提供了治疗导致骨丢失的疾病，病症和障碍（例如骨骼疾病）的方法。还提供了治疗或预防骨量丧失的方法，诱导骨量增加的方法和诱导Wnt活性的方法。

3. 发明申请

US20190338015A1 CELL DEATH INDUCING CHIMERIC ANTIGEN RECEPTORS 审中-公开
公开(公告)号：US20190338015A1
公开(公告)日：2019-11-07
申请号：US16342139
申请日：2017-10-19
申请人： CELLECTIS
发明人： Alexandre JUILLERAT , Philippe DUCHATEAU , Laurent POIROT , Murielle DERRIEN , Donna Marie STONE , Javier Fernando CHAPARRO RIGGERS
IPC分类号： C07K14/705 , C12N5/0783 , A61K35/17 , C07K14/725 , C07K16/28
摘要： The invention relates to cell death inducing chimeric antigen receptors (D-CAR). In particular, the present invention relates to cell death inducing chimeric antigen receptors which comprise at least one death domain in their endodomain, including cell death inducing chimeric antigen receptors comprising within their death domains modifications which attenuate the self-association and/or binding to pro-apoptotic or pro-necrotic adaptor proteins, such as FADD or TRADD. Moreover, the present invention relates to an engineered immune cell expressing at its surface a cell death inducing CAR of the present invention and, optionally, an activating chimeric antigen receptor, wherein the extracellular ligand-binding domains of the cell death inducing CAR and the activating CAR bind to different antigens. The engineered immune cell may furthermore comprise at least one edited (e.g., inactivated) gene selected from TCR genes, immune check point genes, genes involved in drug resistance, and combinations thereof.

4. 发明公开

US20240360196A1 INHIBITORY CHIMERIC ANTIGEN RECEPTORS 审中-公开
公开(公告)号：US20240360196A1
公开(公告)日：2024-10-31
申请号：US18607387
申请日：2024-03-15
申请人： ALLOGENE THERAPEUTICS, INC. , CELLECTIS
发明人： Arvind RAJPAL , Shobha Chowdary POTLURI , Laurent POIROT , Alexandre JUILLERAT , Thomas Charles PERTEL , Donna Marie STONE , Barbra Johnson SASU
IPC分类号： C07K14/705 , A61K35/17 , A61K39/00 , C07K14/725 , C07K16/28 , C07K16/30 , C12N5/0783
CPC分类号： C07K14/70503 , A61K35/17 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/2803 , C07K16/3069 , C12N5/0636 , A61K2039/5156 , C07K2317/622 , C07K2317/76 , C07K2319/03 , C07K2319/70 , C07K2319/74 , C12N2510/00
摘要： The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising

an extracellular domain comprising an antigen binding domain,
a transmembrane domain and,
an intracellular domain
wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein
X1 is an amino acid
X2 is an amino acid
X3 is an amino acid and
X4 is V or I.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式